Brief: Schrödinger Gets Fast Track Status for SGR-1505 in Relapsed/Refractory Waldenström Macroglobulinemia Treatment
27/06/2025 13:06
June 27 (Reuters) - Schrodinger Inc SDGR.O: SCHRÖDINGER RECEIVES FAST TRACK DESIGNATION FOR SGR-1505 FOR THE TREATMENT OF RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA SCHRODINGER INC - SGR-1505 SHOWS FAVORABLE SAFETY PROFILE IN INITIAL DATA SCHRODINGER INC - SGR-1505 SHOWS PRELIMINARY EFFICACY IN MULTIPLE B-CELL MALIGNANCIES Source text: ID:nBwNP6sJa Further company coverage: SDGR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Schrodinger
See all newsBrief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Schrodinger Inc reports results for the quarter ended June 30 - Earnings Summary
Schrodinger Q2 revenue beats estimates, swings to profit
Brief: Schrodinger Q2 Revenue USD 58.889 Million Vs. IBES Estimate USD 47.2 Million
Brief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)